Volpara Solutions releases VolparaDensity 3.1 for use with tomosynthesis systems from multiple manufacturers at SBI

Volpara Solutions today announced the release of VolparaDensity version 3.1 here at the Society of Breast Imaging’s SBI/ACR Breast Imaging Symposium in Orlando, Fla., April 25-28, 2015 (SBI Booth #214). VolparaDensity, the first breast density assessment tool available clinically for use with digital breast tomosynthesis datasets from multiple manufacturers, is already in use at sites in the United States and worldwide.

The latest version of VolparaDensity supports digital mammography from all leading vendors and tomosynthesis data sets from Hologic, GE, and Siemens tomosynthesis systems. Additionally, VolparaDensity 3.1 supports Hologic sites that use C-View synthetic 2D images and GE SenoClaire sites that acquire 2D CC and 3D MLO images. VolparaDensity uses the same algorithm to process both the acquired tomosynthesis projections and the raw data of a conventional 2D mammogram. This reduces the challenges of visually determining breast density based on a review of tomosynthesis slices and the new synthetic 2D images (C-View from Hologic, V-Preview from GE).

“We have been using VolparaDensity for more than two years and find it particularly helpful when assessing breast density in mammograms with a complex dispersion of fibroglandular tissue,” said Dr Kathy Schilling of the Christine Lynn Women's Health and Wellness Center at Boca Raton Regional Hospital in Boca Raton, Fla. “We are now very pleased to be using VolparaDensity together with our GE SenoClaire digital breast tomosynthesis acquisitions. Given the demands of reviewing the stacks of tomosynthesis slices and the new synthetic 2D images, we appreciate the consistent density assessment we get from the Volpara software.”

VolparaDensity 3.1 supports additional features including new configuration flexibility for patient-specific compression pressure calculations and the ability to route patient results by Volpara’s FDA cleared Volpara Density Grades (VDG) which are analogous to the BI-RADS density categories. Based on a site’s imaging protocols for breast density and risk, users can configure the system to automatically send density results for women with very dense breasts to a specific interpreting radiologist or a breast density specialist at the site for review. This automatic routing may help improve the speed with which sites can identify women who would benefit from additional screening, particularly sites that perform same-day adjunctive screening.    

“VolparaDensity, which has been in clinical use since 2010, was developed to be suitable for use with both digital mammography and digital breast tomosynthesis data. This ensures that every woman will receive consistent density assessments based on her actual breast tissue composition, regardless of what system or method of image acquisition is used,” said Ralph Highnam, PhD., Volpara Solutions CEO and Chief Scientist.

VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to determine which women would benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories. To date, more than 4-million women have had their breast density analyzed using VolparaDensity.

For more information: http://www.volparasolutions.com

Trimed Popup
Trimed Popup